GALECTIN THERAPEUTICS INC — Director's Dealing 2019

Apr 2, 2019

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-12-31

Reporting Person: CZIRR JAMES C (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-31	Common Stock	J	1000	$6.00	Acquired	890630	Direct
2018-09-30	Common Stock	J	1000	$6.00	Acquired	891630	Direct

Footnotes

F1: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2018 and 9/30/2018. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend.

F2: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9 and as an involuntary transaction pursuant to court decisions.